Abstract: Methods for depositing on a surface of a substrate are disclosed. Exemplary methods include depositing a silicon oxide material using a cyclical deposition process, and reflowing the material during one or more of the step of depositing and a post-deposition anneal step. Structures including a layer of the material are also disclosed.

Abstract: The present invention addresses the problem of providing an inhibitor for retinochoroidal disorders, in particular, an inhibitor for retinochoroidal scar formation and retinochoroidal atrophy in an epiretinal, intraretinal or subretinal tissue. This problem can be solved by preparing an inhibitor for retinochoroidal disorders which comprises, as an active ingredient, (E)-4-(2-{3-[(1H-pyrazol-1-yl)methyl]-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-yl}vinyl)benzoic acid, an ester thereof or a salt of the same. The inhibitor for retinochoroidal disorders can inhibit collagen atrophy of retinal pigment epithelium cells, fibroblasts, glial cells and the like and thus inhibit retinochoroidal disorders.

Abstract: A rolling bearing includes an inner ring, an outer ring, and a plurality of balls interposed between the inner ring and the outer ring. The inner ring and the outer ring are made of stainless steel. A raceway surface with which the ball is in rolling-contact in each of the inner ring and the outer ring and is a superfinished surface and a coating layer made of a solid lubricating film is formed on the superfinished surface.

Abstract: Provided is a water-purifying agent that is excellent in water purifying performance, can be suitably used in an automated wastewater purification apparatus, and is formed of a granulated product including a mixture of a powder of Corchorus olitorius and a polymeric flocculant, wherein a median diameter of the granulated product is 250 micrometers or greater but 850 micrometers or less.

Abstract: The present invention addresses the problem of providing a novel therapeutic agent for keratoconjunctive disorders. As a means for solving the problem, a therapeutic agent for keratoconjunctive disorders which contains a RAR? agonist as an active ingredient is provided. The therapeutic agent exhibits an excellent ameliorating effect in a keratoconjunctive disorder model, and is therefore useful as a therapeutic agent for keratoconjunctive disorders such as corneal ulcer, corneal epithelial abrasion, keratitis, dry eye, conjunctivitis, chronic superficial keratitis, corneal erosion, persistent corneal disorders, superficial punctate keratopathy, corneal epithelial defects, conjunctival epithelial defects, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis, filamentary keratoconjunctivitis, infectious keratitis, noninfectious keratitis, infectious conjunctivitis and noninfectious conjunctivitis.

Abstract: A rolling bearing device includes a rotary shaft; a housing; a pair of rolling bearings; an outer ring spacer; an elastic member provided in a bottom side of the housing, the bottom side of the housing being a second axial side of the housing, and the elastic member being configured to urge the rolling bearings, the outer ring spacer, and the rotary shaft toward a first axial side; and a retaining ring that is fitted into a circumferential groove provided on an inner periphery in the first axial side of the housing, the retaining ring being in axial contact with the outer ring of the rolling bearing located on the first axial side, and the retaining ring including at least three arc members arranged in a circumferential direction.

Abstract: [Solution] Provided is a plant-derived water purifying agent used for water purification for industrial wastewater, etc. and including a granulated product of a plant powder, such that when a wastewater purifying treatment using the plant-derived water purifying agent is performed by an automated purifying treatment device, the water purifying agent can be suitably used in the automated purifying treatment device. It is more preferable that a Carr's fluidity index of the water purifying agent obtained by measuring 3 items of the water purifying agent, which are an angle of repose, a degree of compression, and a spatula angle be 40 or greater.

Abstract: The present invention addresses the problem of providing an inhibitor for retinochoroidal disorders, in particular, an inhibitor for retinochoroidal scar formation and retinochoroidal atrophy in an epiretinal, intraretinal or subretinal tissue. This problem can be solved by preparing an inhibitor for retinochoroidal disorders which comprises, as an active ingredient, (E)-4-(2-{3-[(1H-pyrazol-1-yl)methyl]-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-yl}vinyl)benzoic acid, an ester thereof or a salt of the same. The inhibitor for retinochoroidal disorders can inhibit collagen atrophy of retinal pigment epithelium cells, fibroblasts, glial cells and the like and thus inhibit retinochoroidal disorders.

Abstract: A bearing housing in which a rolling bearing is built includes a cylindrical inner circumferential surface and an end face formed continuously with an axial end of the inner circumferential surface in an orientation perpendicular to a central axis of the inner circumferential surface. The inner circumferential surface has an annular groove that is radially outwardly recessed around an entire circumference of the inner circumferential surface. A snap ring is attached into the annular groove to reduce displacement of the rolling bearing. A recess recessed in an axial direction and extending in a radial direction is provided in the end face of the bearing housing.

Abstract: The present invention addresses the problem of providing a novel therapeutic agent for keratoconjunctive disorders. As a means for solving the problem, a therapeutic agent for keratoconjunctive disorders which contains a RAR? agonist as an active ingredient is provided. The therapeutic agent exhibits an excellent ameliorating effect in a keratoconjunctive disorder model, and is therefore useful as a therapeutic agent for keratoconjunctive disorders such as corneal ulcer, corneal epithelial abrasion, keratitis, dry eye, conjunctivitis, chronic superficial keratitis, corneal erosion, persistent corneal disorders, superficial punctate keratopathy, corneal epithelial defects, conjunctival epithelial defects, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis, filamentary keratoconjunctivitis, infectious keratitis, noninfectious keratitis, infectious conjunctivitis and noninfectious conjunctivitis.

Abstract: The invention provides a ferritic heat-resistant steel whose creep rupture ductility in a long-term region is improved without detrimental to creep strengths. The ferritic heat-resistant steel has a chemical composition comprising, in % by mass, C: 0.03 to 0.15, Si: 0 to 0.8, Mn: 0.1 to 0.8, Cr: 8.0 to 11.5, Mo: 0.2 to 1.5, (W: 0.4 to 3.0), V: 0.1 to 0.4, Nb: 0.02 to 0.12 N: 0.02 to 0.10 with the balance of iron and inevitable impurities. This steel has a tempered martensite microstructure, and has an improved creep rupture ductility even when there is a load within the elastic limits at temperatures at which the ferritic heat-resistant steel is used, because internal strain or internal stress induced by martensitic transformation is relaxed or released by an intermediate tempering heat treatment in a two-phase state temperature in which a portion of an austenitic phase undergoes martensitic transformation.

Abstract: [Solution] Provided is a water purification agent suitable for use in an automated purification treatment device, when a wastewater purification treatment using a plant-derived water purification agent is performed with the automated purification treatment device. The water purification agent is a granulated product containing a mixture of a plant powder and a polymer coagulant.

Abstract: A faulted condition determination method is designed to detect a chromium content and a nickel content in a predetermined boundary region proximate to a boundary between a high-strength ferrite steel and a weld material in a welded joint in which the high-strength ferrite steel and another steel are welded together using the weld material containing nickel and to thereby determine the faulted condition of the predetermined boundary region based on the chromium content and the nickel content. Accordingly, it is possible to appropriately determine the faulted condition of welding of a replacement part in which a high-strength ferrite steel and another steel are welded together using a nickel-based weld material.

Abstract: A bearing housing in which a rolling bearing is built includes a cylindrical inner circumferential surface and an end face formed continuously with an axial end of the inner circumferential surface in an orientation perpendicular to a central axis of the inner circumferential surface. The inner circumferential surface has an annular groove that is radially outwardly recessed around an entire circumference of the inner circumferential surface. A snap ring is attached into the annular groove to reduce displacement of the rolling bearing. A recess recessed in an axial direction and extending in a radial direction is provided in the end face of the bearing housing.

Abstract: The present invention addresses the problem of providing a novel therapeutic agent for keratoconjunctive disorders. As a means for solving the problem, a therapeutic agent for keratoconjunctive disorders which contains a RAR? agonist as an active ingredient is provided. The therapeutic agent exhibits an excellent ameliorating effect in a keratoconjunctive disorder model, and is therefore useful as a therapeutic agent for keratoconjunctive disorders such as corneal ulcer, corneal epithelial abrasion, keratitis, dry eye, conjunctivitis, chronic superficial keratitis, corneal erosion, persistent corneal disorders, superficial punctate keratopathy, corneal epithelial defects, conjunctival epithelial defects, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis, filamentary keratoconjunctivitis, infectious keratitis, noninfectious keratitis, infectious conjunctivitis and noninfectious conjunctivitis.

Abstract: Disclosed is a speed reduction apparatus including: a casing that accommodates a speed reduction mechanism; an input shaft including a protruding portion protruding from the casing to the outside; a fan provided on the protruding portion of the input shaft; and a fan hood that covers the fan. The fan hood includes a cylindrical portion, and a trumpet-like portion that is connected to the cylindrical portion, and includes an inner surface inclined to be separated away from the input shaft toward a load side. A flow straightening fin is provided on an inner surface of the trumpet-like portion.

Abstract: A porous carbon material wherein a particle diameter is 10 ?m or more but 1 cm or less; wherein a bulk specific gravity is 0.20 g/cm3 or more; and wherein a mesopore volume is 0.10 cm3/g or more.

Abstract: The present invention addresses the problem of providing a novel therapeutic agent for keratoconjunctive disorders. As a means for solving the problem, a therapeutic agent for keratoconjunctive disorders which contains a RAR? agonist as an active ingredient is provided. The therapeutic agent exhibits an excellent ameliorating effect in a keratoconjunctive disorder model, and is therefore useful as a therapeutic agent for keratoconjunctive disorders such as corneal ulcer, corneal epithelial abrasion, keratitis, dry eye, conjunctivitis, chronic superficial keratitis, corneal erosion, persistent corneal disorders, superficial punctate keratopathy, corneal epithelial defects, conjunctival epithelial defects, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis, filamentary keratoconjunctivitis, infectious keratitis, noninfectious keratitis, infectious conjunctivitis and noninfectious conjunctivitis.

Abstract: Provided is a water-purifying agent that is excellent in water purifying performance, can be suitably used in an automated wastewater purification apparatus, and is formed of a granulated product including a mixture of a powder of Corchorus olitorius and a polymeric flocculant, wherein a median diameter of the granulated product is 250 micrometers or greater but 850 micrometers or less.